MindMed's opioid withdrawal drug MM-110 shows safety in healthy people in early-stage study

May 19, 2022 9:02 AM ETMind Medicine (MindMed) Inc. (MNMD)By: Ravikash, SA News Editor

Opioid Withdrawal Symptoms And Depression

AndreyPopov/iStock via Getty Images

Mind Medicine (MindMed) (NASDAQ:MNMD) said its opioid withdrawal therapy MM-110 showed safety in an early stage study in healthy people.

The phase 1 trial, which enrolled 108 people, was conducted at a single site in Perth, Australia.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.